Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts.

de Waal, Reneé; Rabie, Helena; Technau, Karl-Günter; Eley, Brian; Sipambo, Nosisa; Cotton, Mark; Boulle, Andrew; Wood, Robin; Tanser, Frank; Fatti, Geoffrey; Egger, Matthias; Davies, Mary-Ann (2023). Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts. Antiviral therapy, 28(2), p. 13596535231168480. Sage 10.1177/13596535231168480

Preview

Text deWaal_AntivirTher_2023.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (784kB) | Preview

BACKGROUND

WHO guidelines recommend abacavir in first-line antiretroviral treatment for children and neonates. However, there is no approved dose <3 months of age, and data in neonates are limited.

METHODS

We included infants who initiated ART aged <3 months, between 2006 and 2019, in nine South African cohorts. In those who received abacavir or zidovudine, we described antiretroviral discontinuation rates; and 6- and 12-month viral suppression (<400 copies/mL). We compared infants aged <28 and ≥28 days, those weighing <3 and ≥3 kg.

RESULTS

Overall 837/1643 infants (51%) received abacavir and 443 (27%) received zidovudine. Median (interquartile range, IQR) age was 52 days (23-71), CD4 percentage was 27.9 (19.2-38.0), and weight was 4.0 kg (3.0-4.7) at ART initiation. In those with ≥1 month's follow-up, 100/718 (14%) infants discontinued abacavir, at a median of 17.5 months (IQR 6.5-39.5). Abacavir discontinuations did not differ by age or weight category (p = 0.4 and 0.2, respectively); and were less frequent than zidovudine discontinuations (adjusted hazard ratio 0.14, 95% confidence interval 0.10-0.20). Viral suppression at 12 months occurred in 43/79 (54%) and 130/250 (52%) of those who started abacavir aged <28 and ≥28 days, respectively (p = 0.8); 11/19 (58%) and 31/60 (52%) in those who weighed <3 and ≥3 kg, respectively (p = 0.6); and 174/329 (53%) in those on abacavir versus 77/138 (56%) in those on zidovudine (adjusted odds ratio 1.8, 95% confidence interval 1.0-3.2).

CONCLUSION

Our data suggest that abacavir may be used safely in infants <28 days old or who weigh <3 kg.

Interest & Impact

Downloads

4 since deposited on 20 Apr 2023
4 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item